ATRIAL FIBRILLATION IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY: WHICH TACTICS IS OPTIMAL FOR RHYTHM CONTROL STRATEGY?
- Authors: Kuznetsova M.V.1, Tarasov A.V.1, Vinuesa D.I.2, Sambrano V.S.2, Davtyan K.V.1, Drapkina O.M.1
-
Affiliations:
- National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia
- Peoples' Friendship University of Russia
- Issue: Vol 8, No 9 (2022)
- Pages: 129-138
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/276912
- DOI: https://doi.org/10.18565/therapy.2022.9.129-138
- ID: 276912
Cite item
Abstract
Full Text
About the authors
Maria V. Kuznetsova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia
Email: mkuznetsova@gnicpm.ru
PhD in Medicine, cardiologist of the highest category, deputy director for medical work
Aleksey V. Tarasov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia
Email: a730tv@yandex.ru
Dr. med. habil., cardiologist of the highest category, head of the Department of surgical treatment of complicated cardiac arrhythmias and cardiac pacing
Diego I. Vinuesa
Peoples' Friendship University of Russia
Email: diegoismaelvinueza@gmail.com
resident physician in cardiology of the Department of internal medicine with a course in cardiology and functional diagnostics, Medical institute
Victor S. Sambrano
Peoples' Friendship University of Russia
Email: santiagozambrano_md@hotmail.com
resident doctor in the specialty «Cardiology» of the Department of internal medicine with a course of cardiology and functional diagnostics, Medical institute
Karapet V. Davtyan
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of RussiaDr. med. habil., professor, head of the Department of cardiac rhythm and conduction disorders
Oksana M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia
Email: drapkina@bk.ru
Dr. med. habil., professor, academician of the RAS, chief external expert in therapy and general medical practice of the Ministry of Healthcare of Russia, Honored Doctor of the Russian Federation, director
References
- Alphonse P., Virk S., Collins J. et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: A systematic review. Clin Res Cardiol. 2021; 110(4): 544-54. https://dx.doi.org/10.1007/s00392-020-01730-w.
- Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2013; 42(5): 873-79. https://dx.doi.org/10.1016/s0735-1097(03)00827-1.
- Authors/Task Force members; Elliott P.M., Anastasakis A., Borger M.A. et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733-79. https://dx.doi.org/10.1093/eurheartj/ehu284.
- Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104(21): 2517-24. https://dx.doi.org/10.1161/hc4601.097997.
- Wilke I., Witzel K., Munch J. et al. High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. J Cardiovasc Electrophysiol. 2016; 27(7): 779-84. https://dx.doi.org/10.1111/jce.12982.
- Maron B.J., Olivotto I., Bellone P. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39(2): 301-7. https://dx.doi.org/10.1016/S0735-1097(01)01727-2.
- Patten M., Pecha S., Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: Diagnosis and considerations for management. J Atr Fibrillation. 2018; 10(5): 1 556. https://dx.doi.org/10.4022/jafib.1556.
- Kirchhof P., Andresen D., Bosch R. et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380(9838): 238-46. https://dx.doi.org/10.1016/S0140-6736(12)60570-4.
- Singh B.N., Singh S.N., Reda D.J. et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18): 1861-72. https://dx.doi.org/10.1056/nejmoa041705.
- Cosedis Nielsen J., Johannessen A., Raatikainen P. et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012; 367(17): 1587-95. https://dx.doi.org/10.1056/nejmoa1113566.
- Rahimi K., Otto C.M. Heartbeat: Is atrial fibrillation ablation effective in patients with hypertrophic cardiomyopathy? Heart. 2016; 102(19): 1511-12. http://dx.doi.org/10.1136/heartjnl-2016-310468.
- Bonow R.O., Frederick T.M., Bacharach S.L. et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil. Am J Cardiol. 1983; 51(8): 1386-91. https://dx.doi.org/10.1016/0002-9149(83)90317-X.
- Opfermann U.T., Doll N., Walther T., Mohr F.W.Combined mitral valve repair, LVOT myectomy and left atrial cryoablation therapy.Interact Cardiovasc Thorac Surg. 2003; 2(4): 501-2. https://dx.doi.org/10.1016/s1569-9293(03)00129-4.
- Packer D.L., Mark D.B., Robb R.A. et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA. 2019; 321(13): 1261-74. https://dx.doi.org/10.1001/jama.2019.0693.
- Girolami F., Iascone M., Tomberli B. et al. Novel a-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Circ Cardiovasc Genet. 2014; 7(6) :741-50. https://dx.doi.org/10.1161/circgenetics.113.000486.
- Gruver E.J., Fatkin D., Dodds G.A. et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol. 1999; 83(12A): 13H-18H. https://dx.doi.org/10.1016/s0002-9149(99)00251-9.
- Pujadas S., Vidal-Perez R., Hidalgo A. et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: A cardiac magnetic resonance imaging study. Eur J Radiol. 2010; 75(2): e88-91. https://dx.doi.org/10.1016/j.ejrad.2009.12.012.
- Bongini C., Ferrantini C., Girolami F. et al. Impact of genotype on the occurrence of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016; 117(7): 1151-59. https://dx.doi.org/10.1016/j.amjcard.2015.12.058.
- Finocchiaro G., Sheikh N., Biagini E. et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020; 17(1): 142-51. https://dx.doi.org/10.1016/j.hrthm.2019.07.019.
- Peteiro J., Bouzas-Mosquera A., Fernandez X. et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012; 25(2): 182-89. https://dx.doi.org/10.1016/j.echo.2011.11.005
- Llamas-Gomez H., Esteve Ruiz I., Romero Reyes M.J. et al. Atrial longitudinal strain and new onset of atrial fibrillation in a cohort of hypertrophic cardiomyopathy patients. Eur Heart J. 2021; 42(1): ehab724.1611. https://dx.doi.org/10.1093/eurheartj/ehab724.1611.
- Bravo P.E., Luo H.C., Pozios I. et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: An intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016; 17(3): 293-300. https://dx.doi.org/10.1093/ehjci/jev154.
- Maron B.J., Haas T.S., Maron M.S. et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014; 113(8): 1394-400. https://dx.doi.org/10.1016/j.amjcard.2013.12.045.
- Harris K.M., Spirito P., Maron M.S. et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114(3): 216-25. https://dx.doi.org/10.1161/circulationaha.105.583500.
- Савченко М.И., Ковалев Ю.Р., Кучинский А.П. Гипертрофическая кардиомиопатия: фиброз или гипертрофия. Артериальная гипертензия. 2013; 19(2): 148-155. [Savchenko M.I., Kovalev Yu.R., Kuchinsky A.P. Hypertrophic cardiomyopathy: fibrosis or hypertrophy. Arterial'naya gipertenziya = Arterial Hypertension. 2013; 19(2): 148-155 (In Russ.)]. EDN: QAXQXL.
- Spoladore R., Maron M.S., D'Amato R. et al. Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. Eur Heart J. 2012; 33(14): 1724-33. https://dx.doi.org/10.1093/eurheartj/ehs150.
- Dan G.A., Martinez-Rubio A., Agewall S. et al.; ESC Scientific Document Group. Antiarrhythmic drugs - clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018; 20(5): 731-32an. https://dx.doi.org/10.1093/europace/eux373.
- Chung R., Houghtaling P.L., Tchou M. et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin Electrophysiol. 2014; 37(10): 1338-48. https://dx.doi.org/10.1111/pace.12426.
- Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010; 15(4): 55-71
- Габрусенко С.А., Гудкова А.Я., Козиолова Н.А. с соавт. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(5): 269-334
- Santangeli P., Di Biase L., Themistoclakis S. et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: Long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol. 2013;6(6): 1089-94. https://dx.doi.org/10.1161/circep.113.000339.
- Cochet H., Morlon L., Vega M.-P. et al. Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2018; 111(10): 591-600. https://dx.doi.org/10.1016/j.acvd.2018.03.007.
- Couto Pereira S., Rigueira J., Placido R. et al. Hypertrophic cardiomyopathy: CMR to predict dysrhythmic events. Eur Heart J Cardiovasc Imaging. 2022; 23(1): jeab289.334. https://dx.doi.org/10.1093/ehjci/jeab289.334
- Castelo A., Rosa S.A., Fiarresga A. et al. Late gadolinium enhancement in the left ventricular wall is associated with atrial fibrillation in patients with hypertrophic cardiomyopathy.Int J Cardiovasc Imaging. (2022). https://dx.doi.org/10.1007/s10554-022-02642-8.